source
- Novartis board under fire as two late-stage trials fail and CAR-T program pausedNovartis' board is facing heightened investor scrutiny after the Swiss drugmaker reported failures in two pivotal late-phase trials, raising doubts about its capital deployment strategy for growth…
- Mikhail, Davis embody the FDA’s stabilization, Seehafer signals AI revolution is comingNewly solidified in their roles as the heads of CBER and CDER, Karim Mikahil and Michael Davis have been working for months to right the ship that had begun to capsize under former Commissioner Mar…BioSpace · 37m ago↗ source